|
Jul 30
|
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
|
|
Jul 17
|
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
|
|
Jan 12
|
Institutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the company
|
|
Dec 18
|
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
|
|
Dec 2
|
We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully
|
|
Nov 15
|
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
|